Phase 2 Study of Azixa (MPC-6827) for the Treatment of Patients With Recurrent Glioblastoma Multiforme

Inclusion Criteria:

- Have histologically proven malignant Glioblastoma Multiforme in first or second
relapse

- Have failed prior Fractionated External Beam Cranial Irradiation or IMRT

- Be at least 18 years old and with a life expectancy ≥ 8 weeks or ≥ 4 weeks if failed
prior Avastin therapy

- Have a Karnofsky performance status of ≥ 60

- Have adequate bone marrow function, liver function, and renal function before
starting therapy

Exclusion Criteria:

- Have had more than two relapses

- Have had radiosurgery

- Have a cardiac ejection fraction < 50% by MUGA or ECHO

- Have Troponin-I elevated above the normal range

- Have an increasing steroid requirement

- Have MRI evidence at baseline of enlarging or clinically significant intratumor
hemorrhage

- Have active stroke and/or transient ischemic attack not optimally managed

- Have active cardiovascular disease (e.g. sub-optimally managed angina, impending
myocardial infarction, or uncontrolled hypertension)

- Be pregnant or breast feeding

- Have had prior hypersensitivity reaction to Cremophor EL

- Be HIV positive